Hedgehog/Smoothened Inhibitors are a class of compounds that target the edgehog/Smoothened signaling pathway. This pathway plays a crucial role in embryonic development and tissue regeneration. Aberrant activation of this pathway is associated with various cancers. Inhibitors in this category disrupt the signaling cascade, potentially offering therapeutic benefits for conditions like basal cell carcinoma and medulloblastoma. These inhibitors are actively researched for their capacity to block the uncontrolled cell growth characteristic of these diseases, making them a promising avenue in cancer treatment research.